Open Payments

Strong Memorial Hospital

Type
Teaching hospital
Where
Rochester, NY
Medicare CCN
330285
Received
$22,760,402 in 1,509 records, 2024 ($1,874,911 general, $20,885,491 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2024General payment228$1,874,911
2024Research payment1,281$20,885,491

By company

CompanyRecordsAmountYears
AstraZeneca Pharmaceuticals LP20$6,522,6662024
Merck Sharp & Dohme LLC34$2,740,6192024
Celgene Corporation6$1,705,8642024
Kite Pharma, Inc.124$1,556,5742024
PFIZER INC.52$1,270,5102024
Eli Lilly and Company17$861,3512024
Sarepta Therapeutics, Inc.197$580,9492024
ModernaTX, Inc.13$578,2162024
Janssen Research & Development, LLC41$487,5852024
United Therapeutics Corporation82$448,0322024
Genentech, Inc.22$414,7682024
Biogen, Inc.13$381,5302024
Novartis Pharmaceuticals Corporation10$378,7072024
Alexion Pharmaceuticals, Inc.4$342,4962024
ABBVIE INC.32$332,2442024
AstraZeneca UK Limited3$323,1102024
Abbott Laboratories47$315,3922024
Incyte Corporation201$260,3052024
Regeneron Pharmaceuticals, Inc.125$259,5272024
Gilead Sciences, Inc.5$231,2062024
bioMerieux Inc21$206,5142024
BIOTRONIK INC.40$189,4162024
ROCHE MOLECULAR SYSTEMS, INC.16$162,9792024
Takeda Pharmaceuticals U.S.A., Inc.9$143,6632024
Intuitive Surgical, Inc.16$120,8002024
Roche TCRC, Inc.12$112,8802024
LSI SOLUTIONS INC1$96,0852024
Astellas Pharma Global Development5$90,4162024
Immedica Pharma US, Inc.18$83,0572024
Medtronic, Inc.19$82,2362024
Ortho-Clinical Diagnostics, Inc.5$79,3942024
BeiGene, Ltd.2$74,1272024
Stryker Corporation22$73,9642024
HARMONY BIOSCIENCES LLC7$68,8912024
Biosense Webster, Inc.4$68,6972024
National Marrow Donor Program4$67,6302024
Alcon Research LLC3$62,1222024
AngioDynamics, Inc.2$60,0992024
E.R. Squibb & Sons, L.L.C.5$56,3382024
Neurocrine BioSciences, Inc.38$54,3932024
Globus Medical, Inc.4$50,0002024
Neurelis, Inc.3$49,5182024
W. L. Gore & Associates, Inc.4$46,6662024
VENTANA MEDICAL SYSTEMS, INC.14$42,5522024
Kaneka Medical America LLC1$41,6852024
Intercept Pharma Europe Ltd.4$35,9932024
Carestream Health, Inc.5$34,3332024
Medical Device Business Services, Inc.16$34,2302024
Eisai Inc.4$33,6032024
SUN PHARMACEUTICAL INDUSTRIES INC.10$32,3342024

By nature of payment

NatureRecordsAmount
Research payment1,281$20,885,491
Compensation for services other than consulting, including serving as faculty or as a speaker at a v33$623,659
Grant44$347,402
Royalty or License6$247,278
Consulting Fee7$230,128
Long term medical supply or device loan39$190,392
Space rental or facility fees (teaching hospital only)73$177,196
Debt forgiveness10$43,861
Education8$13,830
Charitable Contribution8$1,162

Records

DateCompanyAmountNatureFormProductStudyYear
2024-12-31Merck Sharp & Dohme LLC$1,226,893Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pemb2024
2024-12-31Merck Sharp & Dohme LLC$246,042Research paymentCash or cash equivalentWINREVAIR Biological, CARDIOVASCULARA Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for 2024
2024-12-31Merck Sharp & Dohme LLC$226,095Research paymentCash or cash equivalentWINREVAIR Biological, CARDIOVASCULARAn Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arteri2024
2024-12-31Merck Sharp & Dohme LLC$183,851Research paymentCash or cash equivalentWINREVAIR Biological, CARDIOVASCULARA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Ba2024
2024-12-31AngioDynamics, Inc.$60,000Long term medical supply or device loanIn-kind items and servicesNanoKnife Device, Oncology Surgery2024
2024-12-31Merck Sharp & Dohme LLC$50,207Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit2024
2024-12-31Merck Sharp & Dohme LLC$27,015Research paymentIn-kind items and servicesWINREVAIR Biological, CARDIOVASCULARA Phase 2, Multicenter, Double-blind, Extension Study to Evaluate the Effects of Sotatercept for the Treatment of Combin2024
2024-12-31Merck Sharp & Dohme LLC$19,220Research paymentIn-kind items and servicesWINREVAIR Biological, CARDIOVASCULARA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Ba2024
2024-12-31Merck Sharp & Dohme LLC$18,960Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYA Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pemb2024
2024-12-31Intuitive Surgical, Inc.$18,700Long term medical supply or device loanIn-kind items and servicesDAVINCI XI Device, SURGERY2024
2024-12-31Merck Sharp & Dohme LLC$16,846Research paymentIn-kind items and services Drug, INFECTIOUS DISEASEA Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab-Controlled Study to Evaluate the Safety, Efficacy, an2024
2024-12-31BIOTRONIK INC.$16,500Debt forgivenessCash or cash equivalentIntica Neo 7 HF-T DF-1 IS-1 ProMRI Device, Cardiology/Vascular Diseases2024
2024-12-31Regeneron Pharmaceuticals, Inc.$13,625Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYI-SPY 2 TRIAL (INVESTIGATION OF SERIAL STUDIES TO PREDICT YOUR THERAPEUTIC RESPONSE WITH IMAGING AND MOLECULAR ANALYSIS 2024
2024-12-31Merck Sharp & Dohme LLC$11,984Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2024
2024-12-31Merck Sharp & Dohme LLC$9,945Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Ax2024
2024-12-31Merck Sharp & Dohme LLC$8,382Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYAn Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma 2024
2024-12-31Merck Sharp & Dohme LLC$8,352Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus 2024
2024-12-31Merck Sharp & Dohme LLC$8,049Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYAdjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma# A Randomized, Double-blind P2024
2024-12-31Merck Sharp & Dohme LLC$6,049Research paymentIn-kind items and servicesWINREVAIR Biological, CARDIOVASCULARA Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for 2024
2024-12-31Merck Sharp & Dohme LLC$5,630Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab MK-3475 in comb2024
2024-12-31Merck Sharp & Dohme LLC$5,046Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F2024
2024-12-31Intuitive Surgical, Inc.$5,000Long term medical supply or device loanIn-kind items and servicesDAVINCI XI Device, SURGERY2024
2024-12-31Merck Sharp & Dohme LLC$4,289Research paymentIn-kind items and servicesWINREVAIR Biological, CARDIOVASCULARAn Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arteri2024
2024-12-31Merck Sharp & Dohme LLC$4,089Research paymentIn-kind items and servicesWINREVAIR Biological, CARDIOVASCULARAn Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arteri2024
2024-12-31Intuitive Surgical, Inc.$4,000Long term medical supply or device loanIn-kind items and servicesDAVINCI XI Device, SURGERY2024
2024-12-31Stryker Corporation$3,966Long term medical supply or device loanIn-kind items and servicesMV3 Device, PATIENT CARE - PC2024
2024-12-31Merck Sharp & Dohme LLC$3,697Research paymentIn-kind items and servicesWINREVAIR Biological, CARDIOVASCULARA Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for 2024
2024-12-31AstraZeneca Pharmaceuticals LP$3,110Research paymentIn-kind items and servicesIMFINZI Biological, OncologyA Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Co2024
2024-12-31Merck Sharp & Dohme LLC$3,095Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2024
2024-12-31Intuitive Surgical, Inc.$2,500EducationIn-kind items and servicesDAVINCI XI Device, SURGERY2024
2024-12-31Merck Sharp & Dohme LLC$2,193Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit2024
2024-12-31AstraZeneca Pharmaceuticals LP$1,658Research paymentIn-kind items and servicesA Randomised,Double Blind,Placebo Controlled,Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Par2024
2024-12-31ABBVIE INC.$1,024Research paymentIn-kind items and servicesM23-647 ABBV-101 Ph1 RR NHL FIH2024
2024-12-31Stryker Corporation$882Long term medical supply or device loanIn-kind items and servicesARISE 1000 Ex Device, PATIENT CARE - PC2024
2024-12-31Masimo Corporation$857Long term medical supply or device loanCash or cash equivalentrainbow Acoustic Monitoring Device, Devices2024
2024-12-31Masimo Corporation$857Long term medical supply or device loanCash or cash equivalentrainbow Acoustic Monitoring Device, Devices2024
2024-12-31Masimo Corporation$857Long term medical supply or device loanCash or cash equivalentrainbow Acoustic Monitoring Device, Devices2024
2024-12-31Masimo Corporation$857Long term medical supply or device loanCash or cash equivalentrainbow Acoustic Monitoring Device, Devices2024
2024-12-31Masimo Corporation$857Long term medical supply or device loanCash or cash equivalentrainbow Acoustic Monitoring Device, Devices2024
2024-12-31Masimo Corporation$857Long term medical supply or device loanCash or cash equivalentrainbow Acoustic Monitoring Device, Devices2024
2024-12-31Masimo Corporation$857Long term medical supply or device loanCash or cash equivalentrainbow Acoustic Monitoring Device, Devices2024
2024-12-31Masimo Corporation$857Long term medical supply or device loanCash or cash equivalentrainbow Acoustic Monitoring Device, Devices2024
2024-12-31United Therapeutics Corporation$770Research paymentCash or cash equivalent2024
2024-12-31Stryker Corporation$645Long term medical supply or device loanIn-kind items and servicesISOLIBRIUM Device, PATIENT CARE - PC2024
2024-12-31Stryker Corporation$645Long term medical supply or device loanIn-kind items and servicesISOLIBRIUM Device, PATIENT CARE - PC2024
2024-12-31Masimo Corporation$642Long term medical supply or device loanCash or cash equivalentSET and rainbow SET Device, Devices2024
2024-12-31Masimo Corporation$642Long term medical supply or device loanCash or cash equivalentSET and rainbow SET Device, Devices2024
2024-12-31Masimo Corporation$642Long term medical supply or device loanCash or cash equivalentSET and rainbow SET Device, Devices2024
2024-12-31Masimo Corporation$642Long term medical supply or device loanCash or cash equivalentSET and rainbow SET Device, Devices2024
2024-12-31Masimo Corporation$577Long term medical supply or device loanCash or cash equivalentSET and rainbow SET Device, Devices2024
2024-12-31Masimo Corporation$577Long term medical supply or device loanCash or cash equivalentSET and rainbow SET Device, Devices2024
2024-12-31Masimo Corporation$577Long term medical supply or device loanCash or cash equivalentSET and rainbow SET Device, Devices2024
2024-12-31Masimo Corporation$577Long term medical supply or device loanCash or cash equivalentSET and rainbow SET Device, Devices2024
2024-12-31United Therapeutics Corporation$484Research paymentCash or cash equivalent2024
2024-12-31Stryker Corporation$469Long term medical supply or device loanIn-kind items and servicesNA Device, PATIENT CARE - PC2024
2024-12-31Merck Sharp & Dohme LLC$394Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus 2024
2024-12-31Masimo Corporation$285Long term medical supply or device loanCash or cash equivalentSedLine Device, Devices2024
2024-12-31Masimo Corporation$285Long term medical supply or device loanCash or cash equivalentSedLine Device, Devices2024
2024-12-31Masimo Corporation$285Long term medical supply or device loanCash or cash equivalentSedLine Device, Devices2024
2024-12-31Masimo Corporation$285Long term medical supply or device loanCash or cash equivalentSedLine Device, Devices2024
2024-12-31United Therapeutics Corporation$261Research paymentCash or cash equivalent2024
2024-12-31United Therapeutics Corporation$76Research paymentCash or cash equivalent2024
2024-12-31AstraZeneca Pharmaceuticals LP$59Research paymentIn-kind items and servicesLYNPARZA Drug, OncologyA Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Pla2024
2024-12-30PFIZER INC.$17,500Research paymentCash or cash equivalentCIBINQO Drug, Inflammation & ImmunologyIDENTIFY SERUM BIOMARKERS AND S AUREUS RELATEDDRIVERS OF ATOPIC DERMATITIS SEVERITY2024
2024-12-28PFIZER INC.$29,797Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2024
2024-12-26Roche TCRC, Inc.$13,868Research paymentCash or cash equivalentPhase II study in early stage Parkinson s Disease Patients2024
2024-12-26Immedica Pharma US, Inc.$11,172Research paymentCash or cash equivalentA Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Comp2024
2024-12-26Immedica Pharma US, Inc.$6,192Research paymentCash or cash equivalentA Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Comp2024
2024-12-26Roche TCRC, Inc.$1,972Research paymentCash or cash equivalentPhase II study in early stage Parkinson s Disease Patients2024
2024-12-26Regeneron Pharmaceuticals, Inc.$565Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$565Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Immedica Pharma US, Inc.$554Research paymentCash or cash equivalentA Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Comp2024
2024-12-26Regeneron Pharmaceuticals, Inc.$211Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-25PFIZER INC.$1,069Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2024
2024-12-24United Therapeutics Corporation$2,992Research paymentCash or cash equivalentTYVASO Drug, Idiopathic Pulmonary FibrosisAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2024
2024-12-24United Therapeutics Corporation$2,592Research paymentCash or cash equivalentTYVASO Drug, Idiopathic Pulmonary FibrosisAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2024
2024-12-24United Therapeutics Corporation$2,553Research paymentCash or cash equivalentTYVASO Drug, Idiopathic Pulmonary FibrosisA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2024
2024-12-24United Therapeutics Corporation$2,015Research paymentCash or cash equivalentREMODULIN Drug, Pulmonary Arterial HypertensionA PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A2024
2024-12-24United Therapeutics Corporation$1,957Research paymentCash or cash equivalentTYVASO Drug, Idiopathic Pulmonary FibrosisA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2024
2024-12-24Baxter Healthcare$680Space rental or facility fees (teaching hospital only)Cash or cash equivalentRenal - CRRT Device, Renal2024
2024-12-23Kite Pharma, Inc.$148,582Research paymentCash or cash equivalentPhenotypic and Functional Analysis of Kite CART Cells2024
2024-12-23Gilead Sciences, Inc.$101,000Research paymentCash or cash equivalentSunlenca Drug, HIVPerspectives on Innovative HIV Treatment among Treatment Experienced Black Women Living with HIV Infection (in New York 2024
2024-12-23Gilead Sciences, Inc.$33,000Research paymentCash or cash equivalentDescovy Drug, HIVPrEP knowledge, preferences and initiation among Black and Hispanic/Latine transwomen in two US urban centers2024
2024-12-23Kite Pharma, Inc.$15,400Research paymentCash or cash equivalentPhenotypic and Functional Analysis of Kite CART Cells2024
2024-12-20Alcon Research LLC$44,122Research paymentCash or cash equivalentModeling and testing of different EDOF designs2024
2024-12-20Shape Memory Medical Inc.$2,573Research paymentCash or cash equivalentIMPEDE EMBOLIZATION PLUG Device, Vascular EmbolizationAAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion2024
2024-12-20Shape Memory Medical Inc.$1,794Research paymentCash or cash equivalentIMPEDE EMBOLIZATION PLUG Device, Vascular EmbolizationAAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion2024
2024-12-20Shape Memory Medical Inc.$1,423Research paymentCash or cash equivalentIMPEDE EMBOLIZATION PLUG Device, Vascular EmbolizationAAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion2024
2024-12-20Janssen Research & Development, LLC$530Research paymentCash or cash equivalentERLEADA Drug, OncologyA Randomized Double blind Placebo controlled Phase 3 Study of JNJ56021927 in Subjects with High risk Localized or Locall2024
2024-12-20W. L. Gore & Associates, Inc.$332Research paymentCash or cash equivalentProduct in Development Device, DevicesEvaluation of the GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararena2024
2024-12-19AstraZeneca Pharmaceuticals LP$4,412Research paymentCash or cash equivalentTEZSPIRE Biological, RespiratoryA Multicenter,Single arm,Open label,Post Authorization,Phase 4 Effectiveness and Safety Study of Tezepelumab in Adult an2024
2024-12-19Regeneron Pharmaceuticals, Inc.$2,883Research paymentCash or cash equivalentA PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C2024
2024-12-19Regeneron Pharmaceuticals, Inc.$2,883Research paymentCash or cash equivalentA PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C2024
2024-12-19Regeneron Pharmaceuticals, Inc.$2,832Research paymentCash or cash equivalentA PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C2024
2024-12-19Regeneron Pharmaceuticals, Inc.$2,795Research paymentCash or cash equivalentA PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C2024
2024-12-19Regeneron Pharmaceuticals, Inc.$2,697Research paymentCash or cash equivalentA PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C2024
2024-12-19Regeneron Pharmaceuticals, Inc.$2,697Research paymentCash or cash equivalentA PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C2024
2024-12-19Regeneron Pharmaceuticals, Inc.$2,664Research paymentCash or cash equivalentA PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C2024
2024-12-19Regeneron Pharmaceuticals, Inc.$2,664Research paymentCash or cash equivalentA PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C2024
2024-12-19Regeneron Pharmaceuticals, Inc.$2,664Research paymentCash or cash equivalentA PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C2024
2024-12-19Regeneron Pharmaceuticals, Inc.$2,664Research paymentCash or cash equivalentA PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C2024
2024-12-19Regeneron Pharmaceuticals, Inc.$2,664Research paymentCash or cash equivalentA PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C2024
2024-12-19Regeneron Pharmaceuticals, Inc.$2,664Research paymentCash or cash equivalentA PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C2024
2024-12-19Regeneron Pharmaceuticals, Inc.$2,567Research paymentCash or cash equivalentA PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C2024
2024-12-19Regeneron Pharmaceuticals, Inc.$2,567Research paymentCash or cash equivalentA PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C2024
2024-12-19Regeneron Pharmaceuticals, Inc.$2,533Research paymentCash or cash equivalentA PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C2024
2024-12-19Regeneron Pharmaceuticals, Inc.$2,533Research paymentCash or cash equivalentA PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C2024
2024-12-19Regeneron Pharmaceuticals, Inc.$2,436Research paymentCash or cash equivalentA PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C2024
2024-12-19Regeneron Pharmaceuticals, Inc.$2,436Research paymentCash or cash equivalentA PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C2024
2024-12-19Regeneron Pharmaceuticals, Inc.$2,436Research paymentCash or cash equivalentA PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C2024
2024-12-19Regeneron Pharmaceuticals, Inc.$2,436Research paymentCash or cash equivalentA PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C2024
2024-12-19Regeneron Pharmaceuticals, Inc.$2,436Research paymentCash or cash equivalentA PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C2024
2024-12-19Regeneron Pharmaceuticals, Inc.$2,436Research paymentCash or cash equivalentA PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C2024
2024-12-19Regeneron Pharmaceuticals, Inc.$2,436Research paymentCash or cash equivalentA PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C2024
2024-12-19SUN PHARMACEUTICAL INDUSTRIES INC.$2,233Research paymentCash or cash equivalentExtension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata2024
2024-12-19Regeneron Pharmaceuticals, Inc.$1,826Research paymentCash or cash equivalentA PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C2024
2024-12-19Incyte Corporation$1,740Research paymentCash or cash equivalentA phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita2024
2024-12-18Novartis Pharmaceuticals Corporation$55,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-12-17Kite Pharma, Inc.$39,721Research paymentCash or cash equivalentTecartus Drug, CELLTA Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma2024
2024-12-17Eisai Inc.$18,177Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2024
2024-12-17Kite Pharma, Inc.$4,728Research paymentCash or cash equivalentYescarta Drug, CELLTA Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphom2024
2024-12-17Kite Pharma, Inc.$1,450Research paymentCash or cash equivalentYescarta Drug, CELLTPhase 2, Open-Label Study Evaluating Axi-Cel as a 2nd line therapy in patients with Relapsed/Refractory aggressive B-NHL2024
2024-12-17Kite Pharma, Inc.$1,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-12-17Kite Pharma, Inc.$839Research paymentCash or cash equivalentYescarta Drug, CELLTCollaborative: WAVE 1, A Phase I study of anti-CD19 CAR T-cell therapy with axicabtagene ciloleucel (axi-cel) in patient2024
2024-12-17Kite Pharma, Inc.$800Research paymentCash or cash equivalentYescarta Drug, CELLTA Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Thera2024
2024-12-17Kite Pharma, Inc.$793Research paymentCash or cash equivalentYescarta Drug, CELLTCollaborative: A Phase 2 trial of anakinra for the prevention of CAR-T cell mediated neurotoxicity.2024
2024-12-16Merck Sharp & Dohme LLC$4,158Research paymentCash or cash equivalentWELIREG Drug, ONCOLOGYAn Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma 2024
2024-12-13Abbott Laboratories$239,741Research paymentCash or cash equivalentENSITE PRECISION Device, ELECTROPHYSIOLOGYPrimary Preventive Vt Ablation in High Risk Patients Who Receive a Prophylatic ICD (PRIMARY PREVENT-VT)2024
2024-12-13Biogen, Inc.$75,500Royalty or LicenseCash or cash equivalentSPINRAZA Biological, Neurology2024
2024-12-13United Therapeutics Corporation$6,840Research paymentCash or cash equivalentREMODULIN Drug, Pulmonary Arterial HypertensionA PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A2024
2024-12-13PFIZER INC.$4,438Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2024
2024-12-13United Therapeutics Corporation$2,863Research paymentCash or cash equivalentTYVASO Drug, Idiopathic Pulmonary FibrosisA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2024
2024-12-13United Therapeutics Corporation$2,160Research paymentCash or cash equivalentTYVASO Drug, Idiopathic Pulmonary FibrosisAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2024
2024-12-13United Therapeutics Corporation$2,128Research paymentCash or cash equivalentTYVASO Drug, Idiopathic Pulmonary FibrosisA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2024
2024-12-13Medical Device Business Services, Inc.$1,250GrantCash or cash equivalent2024
2024-12-13United Therapeutics Corporation$780Research paymentCash or cash equivalentREMODULIN Drug, Pulmonary Arterial HypertensionA PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A2024
2024-12-13Regeneron Pharmaceuticals, Inc.$565Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-13Regeneron Pharmaceuticals, Inc.$536Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-13Sarepta Therapeutics, Inc.$42Research paymentCash or cash equivalentSRP-9001-3032024
2024-12-12Immedica Pharma US, Inc.$8,620Research paymentCash or cash equivalentA Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Comp2024
2024-12-12Immedica Pharma US, Inc.$3,000Research paymentCash or cash equivalentA Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Comp2024
2024-12-12Immedica Pharma US, Inc.$2,993Research paymentCash or cash equivalentA Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Comp2024
2024-12-12Immedica Pharma US, Inc.$2,689Research paymentCash or cash equivalentA Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Comp2024
2024-12-12Immedica Pharma US, Inc.$1,649Research paymentCash or cash equivalentA Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Comp2024
2024-12-12Immedica Pharma US, Inc.$1,391Research paymentCash or cash equivalentA Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Comp2024
2024-12-11Incyte Corporation$2,271Research paymentCash or cash equivalentA Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Parti2024
2024-12-11United Therapeutics Corporation$2,145Research paymentCash or cash equivalentREMODULIN Drug, Pulmonary Arterial HypertensionA PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A2024
2024-12-11Incyte Corporation$1,586Research paymentCash or cash equivalentA Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Parti2024
2024-12-11Incyte Corporation$1,586Research paymentCash or cash equivalentA Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Parti2024
2024-12-11Incyte Corporation$1,546Research paymentCash or cash equivalentA Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Parti2024
2024-12-11Medical Device Business Services, Inc.$1,250GrantCash or cash equivalent2024
2024-12-11Medical Device Business Services, Inc.$1,250GrantCash or cash equivalent2024
2024-12-10Medical Device Business Services, Inc.$1,250GrantCash or cash equivalent2024
2024-12-06bioMerieux Inc$4,408Research paymentCash or cash equivalentVITEK2 Device, DiagnosticsETEST IRPA2024
2024-12-06bioMerieux Inc$4,408Research paymentCash or cash equivalentVITEK2 Device, DiagnosticsETEST IRPA2024
2024-12-06Medical Device Business Services, Inc.$3,750GrantCash or cash equivalent2024
2024-12-06Stryker Corporation$2,000Research paymentCash or cash equivalentAUGMENT INJECTABLE PAS2024
2024-12-06Medtronic, Inc.$1,500Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-12-05ABBVIE INC.$334Research paymentCash or cash equivalentA Trial of the Efficacy and Safety of?CVL-865?as Adjunctive Therapy in the Treatment of Focal Onset Seizures2024
2024-12-04Merck Sharp & Dohme LLC$19,223Research paymentCash or cash equivalent Drug, INFECTIOUS DISEASEA Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab-Controlled Study to Evaluate the Safety, Efficacy, an2024
2024-12-04PFIZER INC.$8,464Research paymentCash or cash equivalentPROTONIX Drug, GASTROINTESTINALAN EXPLORATORY MULTICENTER RANDOMIZED DOUBLE BLIND STUDY OF CLINICAL OUTCOMES TOLERABILITY AND SAFETY OF 2 DOSES OF ORAL2024
2024-12-04PFIZER INC.$7,168Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2024
2024-12-04Merck Sharp & Dohme LLC$1,852Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemothera2024
2024-12-03Janssen Research & Development, LLC$1,119Research paymentCash or cash equivalentERLEADA Drug, OncologyA Randomized Double blind Placebo controlled Phase 3 Study of JNJ56021927 in Subjects with High risk Localized or Locall2024
2024-12-02PFIZER INC.$76,733Research paymentCash or cash equivalentTHE MICROBIOLOGY AND CLINICAL OUTCOMES OF MODERATE TO SEVERE ACUTE RESPIRATORY INFECTIONS IN HOSPITALIZED ADULTS AFTER T2024
2024-12-02PFIZER INC.$42,298Research paymentCash or cash equivalentTHE MICROBIOLOGY AND CLINICAL OUTCOMES OF MODERATE TO SEVERE ACUTE RESPIRATORY INFECTIONS IN HOSPITALIZED ADULTS AFTER T2024
2024-12-02PFIZER INC.$38,629Research paymentCash or cash equivalentTHE MICROBIOLOGY AND CLINICAL OUTCOMES OF MODERATE TO SEVERE ACUTE RESPIRATORY INFECTIONS IN HOSPITALIZED ADULTS AFTER T2024
2024-12-02ABBVIE INC.$31,511Research paymentCash or cash equivalentStudy to Evaluate Adverse Events Change in Disease Activity and How Oral ABBV-101 Moves Through the Body in Adult Partic2024
2024-12-02Incyte Corporation$236Research paymentCash or cash equivalentA Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Parti2024
2024-12-01Regeneron Pharmaceuticals, Inc.$149Charitable ContributionCash or cash equivalent2024
2024-11-27AstraZeneca UK Limited$70,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-11-27Sarepta Therapeutics, Inc.$3,564Research paymentCash or cash equivalentSRP-9001-3052024
2024-11-27Sarepta Therapeutics, Inc.$3,088Research paymentCash or cash equivalentSRP-9001-3032024
2024-11-27Zimmer Biomet Holdings, Inc.$1,994Research paymentCash or cash equivalentComprehensive Shoulder System Device, ExtremitiesMDR Comprehensive Primary Micro Stem Titanium Versa-Dial Humeral Head2024
2024-11-27Sarepta Therapeutics, Inc.$1,300Research paymentCash or cash equivalentSRP-9001-3032024
2024-11-27Sarepta Therapeutics, Inc.$1,300Research paymentCash or cash equivalentSRP-9001-3032024
2024-11-26Sarepta Therapeutics, Inc.$44,000Royalty or LicenseCash or cash equivalent2024
2024-11-26United Therapeutics Corporation$7,650Research paymentCash or cash equivalentREMODULIN Drug, Pulmonary Arterial HypertensionA PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A2024
2024-11-26United Therapeutics Corporation$6,840Research paymentCash or cash equivalentREMODULIN Drug, Pulmonary Arterial HypertensionA PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A2024
2024-11-26United Therapeutics Corporation$4,456Research paymentCash or cash equivalentTYVASO Drug, Idiopathic Pulmonary FibrosisAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2024
2024-11-26United Therapeutics Corporation$1,900Research paymentCash or cash equivalentTYVASO Drug, Idiopathic Pulmonary FibrosisAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2024
2024-11-26Immedica Pharma US, Inc.$1,691Research paymentCash or cash equivalentA Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Comp2024
2024-11-25Genentech, Inc.$9,833Research paymentCash or cash equivalentPhase II study of RO7269162 in participants with prodromal to mild AD2024
2024-11-25Janssen Research & Development, LLC$6,756Research paymentCash or cash equivalentTREMFYA Drug, ImmunologyA Phase 2a Multi Center Randomized Double blind Study Evaluating the Efficacy and Safety of Subcutaneously Administered 2024
2024-11-25Kite Pharma, Inc.$4,428Research paymentCash or cash equivalentA Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects with R2024
2024-11-25Medtronic, Inc.$1,500Research paymentCash or cash equivalentCARPEDIEM Device, HematologyCARPEDIEM Study2024
2024-11-25Kite Pharma, Inc.$180Research paymentCash or cash equivalentYescarta Drug, CELLTPhase 2, Open-Label Study Evaluating Axi-Cel as a 2nd line therapy in patients with Relapsed/Refractory aggressive B-NHL2024
2024-11-22Sarepta Therapeutics, Inc.$134,743Research paymentCash or cash equivalentAmondys 45 Drug, Genetic Disease4045-3012024
2024-11-22United Therapeutics Corporation$14,434Research paymentCash or cash equivalentA PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE2024
2024-11-22Stryker Corporation$2,000Research paymentCash or cash equivalentAUGMENT INJECTABLE PAS2024
2024-11-22HARMONY BIOSCIENCES LLC$1,594Research paymentCash or cash equivalentWAKIX Drug, NarcolepsySafety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myoto2024
2024-11-21Janssen Research & Development, LLC$45,594Research paymentCash or cash equivalentA Phase 1 First In Human Open Label Dose Escalation Study of JNJ64407564 a Humanized GPRC5D x CD3 DuoBody Antibody in Su2024
2024-11-21Tanabe Pharma America, Inc.$5,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-11-19Kite Pharma, Inc.$44,170Research paymentCash or cash equivalentTecartus Drug, CELLTA Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma2024
2024-11-19Kite Pharma, Inc.$10,829Research paymentCash or cash equivalentYescarta Drug, CELLTA Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphom2024
2024-11-19Kite Pharma, Inc.$6,975Research paymentCash or cash equivalentYescarta Drug, CELLTA Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Thera2024
2024-11-19HARMONY BIOSCIENCES LLC$5,084Research paymentCash or cash equivalentWAKIX Drug, NarcolepsySafety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myoto2024
2024-11-19Kite Pharma, Inc.$3,887Research paymentCash or cash equivalentYescarta Drug, CELLTCollaborative: WAVE 1, A Phase I study of anti-CD19 CAR T-cell therapy with axicabtagene ciloleucel (axi-cel) in patient2024
2024-11-19United Therapeutics Corporation$2,419Research paymentCash or cash equivalentTYVASO Drug, Idiopathic Pulmonary FibrosisAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2024
2024-11-19United Therapeutics Corporation$2,298Research paymentCash or cash equivalentTYVASO Drug, Idiopathic Pulmonary FibrosisA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2024

The latest 200 records of 1,509.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Monroe CountyRochester city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Rochester, NY, county Monroe County, NY, state New York; placed by its city name.

MeasurePlace (city or town)
Rochester, NY
County
Monroe County, NY
State
New York
Population B01003208,772753,75319,852,366
Population, 2020 census P1211,328759,44320,201,249
Median age B0100233.739.639.8
Under 18 B0100120.9%20.3%20.5%
65 and over B0100113.1%18.8%17.9%
Households B1100193,261318,4287,722,646
Foreign born B050028.2%7.9%22.8%
Median household income B19013$47,213$76,382$85,974
Median family income B19113$57,673$102,166$106,873
Per capita income B19301$31,314$44,107$50,712
Poverty rate B1700127.8%13.6%14.0%
Unemployment rate B230257.9%4.9%6.4%
Civilian labor force B23025105,136391,19710,171,766
Mean commute (minutes) B0801319.319.932.6
Bachelor's degree or higher B1500330.0%41.5%40.2%
Housing units B25001104,479339,4308,585,241
Owner-occupied B2500338.1%63.7%54.3%
Renters B2500361.9%36.3%45.7%
Median home value B25077$139,600$213,700$423,800
Median gross rent B25064$1,081$1,173$1,621
White, not Hispanic B0300236.4%67.7%52.8%
Black B0300234.7%13.5%13.4%
Hispanic or Latino B0300219.6%9.9%19.8%
Asian B030023.2%3.8%9.0%
American Indian and Alaska Native B030020.2%0.1%0.2%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Rochester, NY.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.